metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus gp100
	ipilimumab alone
	MDX010 Ipi vs gp100, 2010 N Engl J Med 2010;363:711-23 Ann. Oncol. 2013; 24:2694-8 Clin. Cancer Res. 2013; 19:2232-9 Cancer 2013; 119:1675-82 NCT00094653	RCT	mML - L2 - all population	ipilimumab	gp100	patients with previously treated metastatic melanoma and had received a previous therapeutic regimen	137 / 136	low	conclusif	demonstrated 34 % decrease in deaths (OS) (PE)
	ipilimumab plus gp100
	MDX010 Ipi plus gp100 vs gp100, 2010 N Engl J Med 2010;363:711-23 Ann. Oncol. 2013; 24:2694-8 Clin. Cancer Res. 2013; 19:2232-9 Cancer 2013; 119:1675-82 NCT00094653	RCT	mML - L2 - all population	ipilimumab plus a gp100 peptide vaccine	gp100	patients with previously treated metastatic melanoma and had received a previous therapeutic regimen	403 / 136	low	conclusif	demonstrated 32 % decrease in deaths (OS) (PE)
versus ipilimumab alone
	Ipilimumab (10 mg/kg)
	Ascierto (ipi 10 vs 3 mg/kg), 2017 Lancet Oncol. 2017; 18:611-622 NCT01515189	RCT	mML - L2 - all population	ipilimumab 10 mg	Ipilimumab 3 mg	Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors,	365 / 362	low	conclusif	demonstrated 16 % decrease in deaths (OS) (PE)
	ipilimumab plus gp100
	MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 N Engl J Med 2010;363:711-23 Ann. Oncol. 2013; 24:2694-8 Clin. Cancer Res. 2013; 19:2232-9 Cancer 2013; 119:1675-82 NCT00094653	RCT	mML - L2 - all population	ipilimumab plus gp100	Ipilimumab	patients with previously treated metastatic melanoma and had received a previous therapeutic regimen	403 / 137	low	inconclusive	statistically significant 51 % decrease in objective responses (ORR)
versus placebo plus SoC
	ipilimumab plus SoC
	CA184-024, 2011 N Engl J Med 2011;364:2517-26 J Clin Oncol 2015;33:1191-6 NCT00324155	RCT	mML - L2 - all population	ipilimumab plus dacarbazine	dacarbazine plus placebo	patients with previously untreated metastatic melanoma, (stage III (unresectable) or stage IV melanoma) with measurable lesions; all patients received dacarbazine.	250 / 252	low	conclusif	demonstrated 28 % decrease in deaths (OS) (PE) demonstrated 24 % decrease in progression or deaths (PFS) (PE) suggested 31 % decrease in deaths (OS) (extension)

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population